Moreover, in AML patients, high expression levels of PVR and CD112 correlated with poor prognosis, thus suggesting that CD155 and CD112 or their cognate receptors may be targeted in cancer immune checkpoint antibody therapy [24,25]. This evidence concerns the gene NECTIN2 and cancer.